Rosenthal, Rachel
,
Cadieux, Elizabeth Larose
Salgado, Roberto
Bakir, Maise Al
Moore, David A.
Hiley, Crispin T.
Lund, Tom
Tanić, Miljana
Reading, James L.
Joshi, Kroopa
Henry, Jake Y.
Ghorani, Ehsan
Wilson, Gareth A.
Birkbak, Nicolai J.
Jamal-Hanjani, Mariam
Veeriah, Selvaraju
Szallasi, Zoltan
Loi, Sherene
Hellmann, Matthew D.
Feber, Andrew
Chain, Benny
Herrero, Javier
Quezada, Sergio A.
Demeulemeester, Jonas
Van Loo, Peter
Beck, Stephan
McGranahan, Nicholas
Swanton, Charles
Article History
Received: 17 August 2018
Accepted: 21 February 2019
First Online: 20 March 2019
Competing interests
: C.S. receives grant support from Pfizer, AstraZeneca, BMS and Ventana. C.S. has consulted for Boehringer Ingelheim, Eli Lilly, Servier, Novartis, Roche-Genentech, GlaxoSmithKline, Pfizer, BMS, Celgene, AstraZeneca, Illumina and the Sarah Cannon Research Institute. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options in and is co-founder of Achilles Therapeutics. S.A.Q. is a co-founder of Achilles Therapeutics. R.R., N.M. and G.A.W. have stock options in and have consulted for Achilles Therapeutics. M.A.B has consulted for Achilles Therapeutics. M.D.H. receives research funding from Bristol-Myers Squibb; is paid consultant to Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs; received travel support/honoraria from AztraZeneca and BMS; and a patent has been filed by the Memorial Sloan Kettering Cancer Center related to the use of tumour mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx.